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Mutations in the p53 tumour-suppressor gene are common genetic
changes found in human cancer (Rady et al, 1992; Greenblatt et al,
1994; Hollstein et al, 1994; Hollstein et al, 1996; Hainaut et al,
1997). The p53 protein is involved in a variety of cellular processes
that regulate cell proliferation and cell survival. In particular, muta-
tions as detected in p53 exons 5–8 seem important, because these
exons are highly conserved regions between species. Mutations in
the p53 gene occur frequently in basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC) of the skin (Brash et al, 1991; Rady
et al, 1992; Campbell et al, 1993; Moles et al, 1993; Zeigler et al,
1993). Analysis of premalignant tissue has shown that mutations in
p53 occur before transition to the carcinoma. Expression of the
mutated p53 protein is maintained throughout late progression
(Ziegler et al, 1994). BCC and SCC predominantly appear on sun-
exposed parts of the body, such as the face and the arms, suggesting
that sun exposure is involved in their genesis. A role for sun expo-
sure in the induction of the p53 mutations is indicated by the notion
that the mutations are almost exclusively C to T or CC to TT transi-
tions at dipyrimidine sites, both hallmarks of UV-induced DNA
damage (Brash et al, 1991; Kress et al, 1992; Kanjilal et al, 1993;
Ziegler et al, 1993). Moreover, in an animal model, frequent
alterations in the p53 gene have been noticed in tumours caused by
UV-B treatment (Kanjilal et al, 1993; van Kranen et al, 1995).
Up to almost 60% of BCCs and SCCs harbour mutations in p53,
most at hotspots affecting p53 function. These findings sharply
contrast with the situation in human melanoma, in which p53
mutations are not commonly detected (Volkenandt et al, 1991;
Castresana et al, 1993; Weiss et al, 1993; Lübbe et al, 1994; Albino
et al, 1994; Florenes et al, 1994; Montano et al, 1994; Sparrow et al,
1995; Hartmann et al, 1996; Papp et al, 1996), with frequencies
ranging from 0 to 6% in tumour samples (Castresana et al, 1993;
Florenes et al, 1994; Lübbe et al, 1994; Papp et al, 1996). However,
mutations in the N-ras gene have been shown to occur in at least
15% of melanomas (van Elsas et al, 1996) and occur more
frequently in tumours from sun-exposed body sites compared with
tumours from intermittently or unexposed sites, implicating sun
exposure in the aetiology of these melanomas (van Elsas et al,
1996). This prompted us to search for p53 mutations in part of the
melanoma series screened for N-ras (van Elsas et al, 1996), in order
to investigate a possible correlation between the occurrence of p53
mutation and sun exposure. Our data show that p53 mutations
occur with a higher frequency in primary melanomas than in metas-
tases. A role for UV in the origin of the p53 mutations is suggested
by the finding that metastases with mutations in p53 were exclu-
sively located on sun-exposed body sites.
MATERIALS AND METHODS
Tumour material
Melanoma material was collected through the Melanoma
Cooperative Group of the European Organization for Research
and Treatment of Cancer. Paraffin-embedded samples as well as
purified DNA preparations were used. Of each series of paraffin
slides (usually ten slides of 5–10 mm), one was stained with
haematoxylin and eosin and regions with more than 70% of
tumour cells were indicated by the pathologist. These regions were
scraped from the unstained slides for single-strand conformational
protein (SSCP) analysis.
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exposure status) was as follows: 2/19 lentigo maligna melanoma
(LMM) (chronically exposed), 5/19 nodular melanoma (NM)
(three chronically, two intermittently exposed), 8/19 superficial
spreading melanoma (SSM) (four chronically, four intermittently
exposed) and 1/19 unclassified malignant melanoma (MM) (inter-
mittently exposed). The metastases were derived from patients
with the following primary melanomas: 2/32 nodular melanoma
(one chronically, one intermittently exposed), 4/32 superficial
spreading melanoma (one chronically, three intermittently
exposed), 8/32 unclassified malignant melanoma (four chroni-
cally, four intermittently exposed) and 18/32 unknown.
The following melanoma cell lines established or subcloned in
our laboratory were entered in this study: 513D, 530, 453A0,
518A2, 9304, 607B, 8823, 136-2, 603, 610, 634, 9007, IGR39D
and DNA from cell lines, MM96, MM127, MM170, MM200,
MM229, MM253, MM329, MM369, MM370, MM383, MM386,
MM409, MM415, MM446, MM455, MM472, MM485 and
MM488 was kindly provided by Dr N Hayward (Queensland
Institute of Medical Research, Brisbane, Australia).
PCR-SSCP
DNA was isolated as previously described (van Elsas et al, 1996).
PCR analysis was carried out by using 1 ml of the DNA extract
with primers specific for p53 exons 5–9 that were either derived
from the primary p53 sequence or described by others (Lehman
et al, 1991; Murakami et al, 1991; Hsiao and Haas, 1996; these
primer sequences are available upon request). AmpliTaq DNA
polymerase and buffer (Perkin Elmer, Norwalk, CT, USA) was
used and enzyme was added after the first denaturing step in the
polymerase chain reaction (PCR) reaction. The outer primers were
used to amplify the DNA of the exons of interest by using the
following cycling programme: 5 min at 94°C (10 s at 94°C, 2 min
at 50°C, 2 min at 72°C) for 40 cycles followed by 5 min at 72°C.
PCR products were purified by agarose gel electrophoresis. Bands
of expected size were cut out of the gel and spun through the filter
of a 1000-ml filter tip (Corning Costar, Acton, MA, USA).
Subsequently, the DNA was used for a second round of PCR with
nested primer sets (available upon request) and subjected to SSCP
analysis as described previously (van Elsas et al, 1996).
DNA sequencing
The DNA from the first amplification round was used for
direct sequencing. We pretreated the samples with exonuclease
I/shrimp alkaline phosphatase (Amersham, Buckinghamshire,
UK; Nederland, The Netherlands) followed by direct sequencing
with the Thermo Sequenase Cycle Sequencing kit (Amersham)
using one of the nested primers as sequencing primer.
PCR products were cloned in a TA vector (Invitrogen, Carlsbad,
CA, USA). After transformation, at least six clones were picked
and sequenced using the M13 Universal Sequencing Primer
(Pharmacia, Uppsala, Sweden) and the USB T7 Sequenase version
2.0 DNA Sequencing kit (USB, Cleveland, OH, USA) (Lehman et
al, 1991; Murakami et al, 1991; Hsiao and Haas, 1996).
Western analysis
Whole-cell extracts were prepared using 0.14 M sodium chloride,
0.2 M triethanolamine, 0.2% sodium deoxycholate and 0.5%
Nonidet P40, supplemented with 1 mM phenylmethylsulphonyl
fluoride and 0.2 mg ml–1 aprotinin. Extracts were freeze–thawed
twice and centrifuged to remove debris. Fifteen micrograms of
total protein was separated by sodium dodecylsulphate–10% poly-
acrylamide gel electrophoresis and blotted to an Immobilon-P
membrane (Millipore, Bedford, MA, USA). All incubations and
wash steps were done in 1% non-fat dry milk in Tris-buffered
saline supplemented with 0.2% Tween-20. Immunodetection was
performed using the anti-p53 DO-1 antibody (0.1 mg ml–1,
Oncogene Research Products, Cambridge, MA, USA). Primary
antibody was detected using sheep anti-mouse conjugated to
peroxidase (1:4000, Amersham) and visualized using ECL
according to the manufacturers’ instructions (Amersham). The
membrane was exposed to Fuji RX X-ray film for 1 min.
RESULTS
To investigate p53 mutation frequency and a possible relationship
with sun exposure, we analysed a panel of melanoma specimens
previously screened for N-ras. Fifty-one tumour specimens
(primary melanomas and metastases) derived from primary
tumours exposed to chronic sunlight and a number of melanoma
cell lines for comparison were analysed. In total, DNA from 19
primary tumour samples, 32 metastatic melanoma samples and 30
cell lines were investigated by SSCP analysis and subsequent
sequence analysis to define the mutations.
Cell lines
Exons 5–9 of p53 were examined by PCR-SSCP, and mutant
samples were sequenced. Figure 1A shows the result of a repre-
sentative analysis. Eight out of 30 samples (27%) contained muta-
tions (Table 1), and sequence analysis of a typical deletion in cell
line IGR39D at codon 229 (ACA to A) is shown in Figure 1B. All
mutations led to an aberrant p53 protein, with 5/8 present in exon
7, while the other three were found in exons 6, 8 and 9. Five of
these mutations were present in cell lines established in our own
laboratory and therefore p53 expression was analysed using DO-1
antibody, which recognizes both wild-type and mutated p53. Four
cell lines (518A2, 136-2, 607B and 8823) clearly showed over-
expression of the p53 protein on Western blots as compared with
nine other cell lines with wild-type p53 expression (Figure 2). This
indicates that mutation of the p53 protein leads to an in vivo
biologically altered protein. The fifth cell line (IGR39D) weakly
expresses a truncated p53 protein of approximately 36 kDa as a
result of the frameshift mutation (result not shown).
Tumours
Whereas analysis of the primary tumours showed a similar
percentage of mutations as the cell lines (6/19, 32%, Table 2),
sequence analysis demonstrated that four of the nine mutations
detected in these six primary tumours were silent third base-pair
substitutions. This suggests that these mutations were induced in
already existing tumours and did not contribute to the process of
tumour formation. Of 19 primary tumours, the histology was known
for 16 (see Materials and methods). Eight were SSMs, five were
NMs and two were LMMs, that both harbouring a p53 mutation.
No statistically significant correlation between the type of mate-
rial (primary tumour, metastasis or cell line) and p53 mutation
could be detected (P = 0.107, Table 2), although an unexpected
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observed. If the data from the cell lines are left out of the cross
table, the chi-square analysis yields a highly significant absence of
mutations in the group of metastases (3/32 = 9%) as compared
with the group of primary tumours (P = 0.044, Table 2).
Strikingly, in contrast to the primary tumours, all three p53 muta-
tions in these metastases were missense mutations resulting in an
altered p53 protein (see Table 1).
The histology of 14 primary tumours of this group of 32 metas-
tases was similar to the group of primary melanomas (4/14 SSM,
2/14 NM), except that more melanomas with unclassified
histology (8/14 MM) and no LMM were present among these
lesions. The anatomical origin of the primary tumours of the
metastases did not differ from that of the group of primary tumours
(results not shown). The p53 mutations in this group were in a
metastasis derived from an SSM, an MM and from a melanoma of
unknown histology (Table 1).
Correlation with sun exposure
A possible explanation for the different p53 mutation frequencies
in primary tumours and metastases is that sun exposure is involved
and that primary tumours and metastases are located at different
sites of the body. Indeed, all of the metastases with a p53 mutation
(3/3) were localized on sun-exposed body sites, as opposed to only
24% (7/29) of those carrying wild-type p53 (P = 0.007, Table 3).
These data confirm that sun exposure might be involved in the
induction of the mutations. Such a conclusion could not be derived
from the analysis of the primary tumours as we preselected largely
for tumours from chronically or intermittently exposed sites.
However, when the primary tumours are classified according to
intermittent and chronic sun exposure (Table 4), there appears to
be a slight trend, although not statistically significant, towards
more p53 mutations at chronically exposed sites: 4/9 (44%) as
compared with 2/8 (25%) at intermittently exposed sites.
Mutation site
In the cell lines, mutations in the p53 gene were mainly localized in
exon 7 (five times vs once in exons 6, 8 and 9; see Table 1). In the
tumours, however, only one mutation was in exon 7 (sample 581,
see Table 1), with one in exon 5, four in exon 6 and three in exon 8.
As we only analysed exons 5–8, mutations in other exons cannot be
excluded. However, analysis of exon 9 from the cell lines and 22
tumour samples, revealed that only one sample (cell line MM 446)
contained a mutation. In the cases of multiple mutations in one
single tumour sample (cell line 8823 and primary tumour samples 1
and 257), these were found within the same exon.
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Figure 1 Analysis of exon 7 in p53 in melanoma cell lines. (A) PCR–SSCP analysis. PCR fragments of exon 7 of the p53 gene were subjected to SSCP gel
electrophoresis using 5% glycerol and 0.5 ´ TBE. Lane 1, 136–2; lane 2, 513D; lane 3, 530; lane 4, 603; lane 5, 607B; lane 6, 610; lane 7, IGR39D; lane 8,
518A2. Samples with a mutation are indicated by an asterisk (*). SS, single stranded DNA bands; DS, double-stranded DNA bands. (B) Nucleotide sequence
analysis. The sequence of DNA from cell line IGR39D containing codon 229 is shown. The numbers on the right represent codon numbers of the wild-type p53
protein. A frame shift deletion of two nucleotides (CA) has occurred as indicated
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ADISCUSSION
p53 mutation frequencies in skin cancer
The results presented here clearly show a more frequent occurrence
of mutated p53 alleles in melanoma than reported in most previous
studies, i.e. 21% vs 0–6% in tumours (Castresana et al, 1993;
Florenes et al, 1994; Lübbe et al, 1994; Papp et al, 1996) and 27%
vs 11–25% in cell lines (Volkenandt et al, 1991; Weiss et al, 1993;
Albino et al, 1994; Papp et al, 1996). One report describes p53
mutations in exons 7 and 8 in 15% of the tumours studied (Akslen
et al, 1998). In our series of 19 primary melanomas, the p53 muta-
tion frequency amounts to not less than 32%. Surprisingly, only 9%
of the metastatic lesions show a p53 mutation. This is at variance
with a recent study (Hartmann et al, 1996) reporting that 20% of
the tumours within a series of 20 metastatic melanomas had p53
mutations. This study, however, confirms our finding that the p53
mutation frequency in non-cultured melanomas on average
(primaries and metastases together) is relatively high. The discrep-
ancies with earlier reports (Castresana et al, 1993; Florenes et al,
1994; Lübbe et al, 1994; Papp et al, 1996) may be due to a higher
sensitivity of our PCR–SSCP method gained by selection of
tumour cells on the slides. In fact, tumour-rich parts of the paraffin-
embedded melanomas were indicated by the pathologist and selec-
tively removed for DNA extraction. This reduces the background
wild-type p53 signals derived from normal surrounding tissue,
allowing easier detection of mutations. The low number of muta-
tions in the metastases as compared with primary tumours in our
series may be explained by the location of the metastases; almost
all were internal metastases and thus not exposed to sunlight. These
data suggest that sun exposure may be important in the induction of
mutations in p53, but that these mutations are not important for
progression from primary melanoma to metastasis. No correlation
between p53 mutation and the histological classification of the
primary tumours could be made (see Table 1).
A role for sun exposure?
A role for sun exposure in the aetiology of the p53 mutations in
our series of melanomas is suggested by a number of observations.
Firstly, the nature of the mutations is typical for UV induction (see
Table 1): 12/13 mutations in the tumours are either C:G to T:A
transitions (11/13) or are located at CC dipyrimidine sites (5/13,
including mutations with GG in the opposite strand). Moreover, in
the cell line panel, 6/8 mutations were C to T transitions, including
a CC to TT transition, which is thought to be caused exclusively
by UV exposure. Secondly, no fewer than 13 of the 21 mutations
found here in vivo are located at the same codons as loss of func-
tion mutations induced by UV irradiation in p53 cDNA in vitro
(Moshinski and Wogan, 1997), suggesting that these positions are
hotspots for UV damage. Strikingly, four of these mutations
924 SF Zerp et al
British Journal of Cancer (1999) 79(5/6), 921–926 © Cancer Research Campaign 1999
Table 1 p53 mutations in melanoma cell lines, metastases and primary tumours
Mutated Amino acid
Sample Material Histology Sun exposure condon Mutation substitution
518A2 Cell line 213 CGA®CAA Arg®Gln
136-2 Cell line 246 ATG®AGG Met®Arg
607B Cell line 238 TGT®TAT Cys®Tyr
IGR39D Cell line 229D2 op TGT®T.. Frameshift
8823 Cell line 247/248 AAC®ACC Asn®Thr
CGG®TGG Arg®Trp
MM446 Cell line 315 CCA®TTA Pro®Leu
MM386 Cell line 290 CGC®CAC Arg®His
MM229 Cell line 248 CGG®CAG Arg®Gln
581 Metastasis primary,?a Intermittent 252 CTC®CCC Leu®Pro
783 Metastasis primary, SSMa Intermittent 213 CGA®TGA Arg®Stop
68 Metastasis primary, MM Chronic 278 CCT®CTT Pro®Leu
1 Primary NM Chronic 266 GGA®GAA Gly®Glu
294 GAG®GAA Glu®Glu
72 Primary LMM Chronic 182 TGC®TGT Cys®Cys
intron 8 G®A
250 Primary NM Intermittent 290 CGC®CAC Arg®His
253 Primary SSM Intermittent 189 GCC®GCT Ala®Ala
257 Primary SSM Chronic 187 GGT®AGT Gly®Ser
198 GAA®AAA Glu®Lys
209 AGA®AAA Arg®Lys
266 Primary LMM Chronic 191 CCT®CCA Pro®Pro
a?, unknown histology; SSM, superficial spreading melanoma; MM, unclassified malignant melanoma; NM, nodular melanoma; LMM, lentigo malignant melanoma.
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Figure 2 Expression of p53 in melanoma cell lines. Melanoma cell lines as
indicated were analysed by Western blotting with monoclonal antibody DO-1,
that recognizes both wild-type and mutant p53. Numbers on the left indicate
the molecular weights of the marker proteinsconstituted exactly the same base change as was found after in
vitro irradiation (Moshinski and Wogan, 1997) (twice at codon 213
and once each at codons 238 and 266). Moreover, two mutations in
our series were identical to mutations induced in vitro, but at other
codons (codon 198 and codon 209). This further stresses the role
for UV in the induction of these particular mutations. Finally, of
the 32 metastases analysed, only the three skin metastases, which
were exposed to sunlight, harbour a p53 mutation (Table 3).
p53 mutation not essential for melanomagenesis
In contrast to the N-ras mutations, four of the nine p53 mutations
detected in primary tumour samples (nos. 1, 72, 253 and 266; see
Table 1) were silent third basepair substitutions, leading to an
unchanged p53 protein in three samples (sample 1 has, in addition,
a missense basepair substitution). Apparently, the mutations in the
p53 gene found in these samples do not contribute to the trans-
formed state of the tumour. Three of these mutations are C to T
transitions and, therefore, may have from a UV hit in an already
established melanoma. The alternative explanation, that a normal
melanocyte with a silent p53 mutation has converted to a melanoma
by other genetic alterations, is unlikely, as several primary
melanomas in our series had multiple p53 mutations, and the prob-
ability that a single cell acquires so many different mutations in a
single gene seems negligible. This would imply that the genesis of
these p53 mutations is a late event in tumour evolution and, as such,
does not play a role in the pathogenesis of the melanomas in our
series. This conclusion is corroborated by two further findings.
First, we noticed that, in a number of cases with a mutation, only
faint bands were seen in the SSCP analysis for the mutant confor-
mation, whereas the wild-type bands were much stronger. This
indicates that the percentage of cells in these tumours containing
mutations in p53 is low, and that these mutations are indeed late
events. Second, 29/32 metastases had no mutation, whereas the
three tumours with a p53 mutation were the only ones at sun-
exposed body sites. This again indicates that the mutations have
occurred after the process of metastasis and that UV may be impor-
tant in their induction.
In contrast to the primary tumours, the cell lines contained all
missense mutations in p53 leading to the production of an altered
protein, which was either overexpressed or stabilized or, in the
case of cell line IGR39D, inactivated by an early stop codon
leading to a truncated protein. The mutations, however, are prob-
ably not representative of the original melanoma, but rather have a
role in conferring an in vitro growth advantage over cells with
functional p53 (Moyret et al, 1994).
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